Qsymia and Belviq and the Previously Approved Weight-loss Drugs

The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research knows that obesity increases the risk of diabetes, stroke, hypertension, heart attack and certain types of cancer – the very reason why it is a major cause of public health concern – definitely not good news for the millions of obese and overweight individuals in the United States, who make up about 35.7 percent of the total population of U.S. adults (in the country). The FDA considers an individual obese if he or she has a Body Mass Index (BMI) of 30 or higher; overweight are those with a 27 (or higher) BMI.

Obesity is a worldwide health concern and, around the world, obese people are in constant search for over-the-counter, prescription or supplement drugs that will help them lose lots of unwanted fats and weight.

The last prescription drug that was approved by the FDA was Xenical (Orlistat 120mg), but and this was still in 1999. Previous to this, there were Meridia (marketed under the names Reductil and Sibutrex), Ephedra (which, once upon a time, caused frenzy among dieters), Aminorex (another appetite suppressant over-the-counter drug that Germans, Austrians and the Swiss were so crazy about between 1965 and 1972), Rimonbant or Acomplia (which was so famous in the UK, but never got approved in the US), Fen-Phen (which is fenfluramine used with phentermine, another diet drug), and the over-the-counter supplements like TrimSpa and Metabolife.

These drugs, though, were short-lived, most being pulled out of the US market and banned from being sold, due to their severe side-effects, some even causing death. It is this need for a new and safe dietary pill that those who were obese and overweight needed to consume and which doctors needed to be able to prescribe that made the entry of the two new weight-loss drugs, Qsymia and Belviq, a perfectly good news for many Americans.

Qsymia is manufactured by Vivus, Inc., and was formerly sold under the name of Qnexa. It is the combination of two other FDA-approved drugs, phentermine and Topamax or topiramate (its extended-release formulation). Qsymia makes food less tasty, increases the burning of calorie and the feeling of being full; it is supposed to be an addition to a reduced-calorie diet and exercise.

Belviq or lorcaserin hydrochloride, which is produced by Arena Pharmaceuticals Inc., is a serotonin 2C receptor agonist and is supposed to be taken in combination with regular exercise and a healthy diet. The FDA suggests, however, that if after 12 weeks of use Belviq is not able to shed off at least 5% of body weight, then its use ought to be stopped as further use may no longer produce good results.

Both Qsymia and Belviq have sadly been linked to a number of different severe side-effects already, despite just being two years in the market. The law firm of Williams Kherkher is definitely one firm totally aware of this, as well as of the increasing lawsuits being filed against the weight-loss drugs’ manufacturers. In fact, to help those who have been harmed by either of the drugs, Williams Kherkher clearly explains on its website the drugs’ uses and reported side-effects. The site also states why victims will need to be represented by lawyers, who are knowledgeable about the issue, and the best legal options the victims can decide on.